Reviewer's report

Title: uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer

Version: 1 Date: 27 August 2008

Reviewer: Tatiana Oberyszyn

Reviewer's report:

Major compulsory Revisions:
The current study was designed to determine the effects of two doses of celecoxib on levels of uPA, PAI-1 and PGE2 in NAF and plasma of women at increased risk of breast cancer development. There are inherent difficulties in carrying out these types of studies however the data presented here are mostly negative. While the observed trends are suggestive, the lack of statistically significant changes is a problem that potentially could be overcome with a larger N per group.

Outside of the lack of statistical significance, several concerns exit with the manuscript in its current form:

1. The authors did not discuss how the participants were randomized into the two dose groups or how they decided upon the number of women assigned in each group.

3. What was the rational for only treating for 2 weeks?

3. It is not clear why PGE2 was not inhibited by celecoxib in the current study as the authors had shown previously? Some discussion of why the authors believe this happened should be

Minor Essential Revisions:

1. In the 400 mg celecoxib uPA data in Table 2 were the overall and premen levels really identical both at pre and post treatment?

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:
I declare that I have no competing interests